Arrowhead Pharmaceuticals Secures $916.6M in Combined Convertible Notes and Equity Offering

summarizeSummary

Arrowhead Pharmaceuticals announced a significant capital raise of up to $916.6 million through 0.00% convertible senior notes and a concurrent equity offering, providing substantial funding for its pipeline and commercialization efforts.

check_boxKey Events

• Massive Capital Raise

  The company is raising up to $916.6 million through a combination of convertible senior notes and a concurrent equity offering.

• Favorable Convertible Note Terms

  The $700 million convertible notes carry a 0.00% interest rate and an initial conversion price of $87.07, a substantial premium to the current stock price.

• Dilution Mitigation

  Capped call transactions were entered into to reduce potential dilution from note conversion, with a cap price of $119.33 per share.

• Concurrent Equity Offering

  An additional $216.6 million is being raised through an equity offering priced at $64.50 per share, closely aligned with the current market price.

auto_awesomeAnalysis

This filing details a substantial capital raise by Arrowhead Pharmaceuticals, totaling up to $916.6 million through a $700 million convertible senior notes offering and a concurrent $216.6 million equity offering. The convertible notes bear 0.00% interest and have an initial conversion price of $87.07, a significant premium over the current stock price of $65.00. The company also entered into capped call transactions to mitigate dilution up to a cap price of $119.33. The concurrent equity offering is priced at $64.50 per share, very close to the current market price. The proceeds will be used for general corporate purposes, including R&D, clinical trials, commercialization activities for its recently approved drug REDEMPLO, and potential prepayment of high-interest debt. This financing significantly strengthens the company's balance sheet, extending its operational runway into fiscal year 2029, and de-risks its long-term growth strategy. The favorable terms of the convertible notes, including the high conversion premium and capped calls, are particularly advantageous for the company.